A Biomimetic Combination of Actives Enhances Skin Hydration and Barrier Function via Modulation of Gene Expression: Results of Two Double-Blind, Vehicle-Controlled Clinical Studies

Silke Altgilbers a  Frank Rippke a  Alexander Filbry a  Stefanie Conzelmann a
Jens-Peter Vietzke a  Thorsten Burkhardt a  Dörte Segger b
Dennis Roggenkamp a  Elke Grönniger a

aResearch and Development, Beiersdorf AG, Hamburg, Germany; bSGS Institut Fresenius GmbH (former SIT Skin Investigation and Technology), Hamburg, Germany

Keywords
Xerosis cutis · Dry skin · Gene expression · Urea · Natural moisturizing factor · Ceramide

Abstract
Introduction: Xerosis cutis is characterized by a decreased stratum corneum (SC) hydration and an impaired skin barrier function. Urea, the most prevalent natural moisturizing factor (NMF), is currently considered the gold standard. Its efficacy can further be increased by combining urea with other NMF and skin barrier lipids (SBLs). Objective: We set out to evaluate physiological effects of a novel functional moisturizer containing 10% urea, additional NMF components, and a combination of SBLs on skin hydration and skin barrier integrity on a cellular and phenotypic level in female volunteers suffering from xerosis. Methods: Two double-blind, vehicle-controlled clinical studies were conducted. In the first study, 44 female subjects having very dry body skin applied the moisturizer or its vehicle twice daily to their volar forearms. Twenty-four hours after a single product application as well as 24 h after 2 weeks of treatment, SC hydration was measured by corneometry. Skin barrier function was assessed by transepidermal water loss 24 h and 48 h after 2 weeks of regular use. Twenty-four hours after 2 weeks of application, skin tape stripping was performed, and urea content was determined in the 3rd strip by means of high-performance liquid chromatography/tandem mass spectrometry. In the second study, 22 women with self-reported very dry skin applied the moisturizer or vehicle twice daily to their volar forearms for 2 weeks. Then, suction blister samples were obtained for gene expression analysis using RT-PCR. Results: Application of the actives led to significantly improved skin hydration and barrier function at all points in time. Compared to the vehicle, application of the moisturizer for 2 weeks resulted in a significant increase in SC urea content. Relative gene expression data revealed significant upregulation of genes associated with skin barrier function, hydration, differentiation, and lipid metabolism compared to the vehicle-treated area. Conclusions: Overall, our data demonstrate that the functional moisturizer provides an adequate bioavailability of urea and a beneficial biophysical impact on xerotic skin. Topical treatment with a combination of urea and additional NMF as well as SBL can modify mRNA expression of important epidermal genes stimulating cellular processes and functions. The well-tolerated novel

Dennis Roggenkamp and Elke Grönniger contributed equally.
Introduction

Xerosis cutis is a common skin condition. Many patients experience dry, scaly, and rough skin often associated with reduced elasticity and wrinkling. Further, erythema as well as fissures or rhagades, especially of the feet, can develop [1]. Dry skin may feel irritated and tight and is also prone to pruritus. Especially, this pruritus can lead to a considerable impairment in patients’ quality of life [2, 3]. The predominantly affected parts are skin areas with a reduced density of sebaceous glands such as the outer aspects of lower legs, forearms, hands, and feet.

Xerosis cutis is characterized by a decreased water content and an impaired barrier function of the stratum corneum (SC). In many cases of dry skin, a lack of natural moisturizing factor (NMF) and skin barrier lipids (SBLs) has been shown in the SC. NMF consists of a complex, hydroscopic composition mainly comprising free amino acids, pyrrolidone carboxylic acid (PCA), lactates, and urea. SBLs, which constitute a hydrophobic domain in the SC, are predominantly composed of ceramides (40–50%), cholesterol (25%), and free fatty acids (10–15%) [1, 4–7].

For the treatment of dry skin conditions, moisturizing formulas containing humectants are essential. Urea, which has been used for more than a century in the management of dermatological disorders, is currently considered the gold standard in the treatment of xerosis cutis [1, 6]. As an element of the NMF, urea represents an important hygroscopic component and thus contributes to the maintenance of skin hydration [8]. Urea improves the skin barrier function as well as cutaneous defense and hydration mechanisms. It enhances penetration of active ingredients and exhibits antipruritic as well as keratolytic effects [1].

Urea therapy has been associated with few adverse effects and is generally well tolerated by xerotic skin. Both the safety and efficacy of urea have been largely established over the past hundred years [6–10].

The mode of action of urea, though, has not yet been fully understood. Due to its hygroscopic properties, urea has long been considered as “just” a humectant. However, more recent studies demonstrate that urea is also actively involved in epidermal gene regulation impacting keratocyte differentiation, lipid synthesis, AMP production, epidermal permeability, and barrier function [6, 11, 12]. We hypothesized that not only urea, as reported by Grether-Beck and others [6, 11, 12], but also its combination with other NMF components and SBLs can influence epidermal gene expression, thus impacting dry-skin physiology beyond a physical mode of action. According to this hypothesis, we sought to determine the effect of a novel functional moisturizer containing a biomimetic combination of 10% urea and additional NMF components (lactate, amino acids, and PCA) as well as SBLs (ceramide NP, cholesterol, and linoleic acid-rich sunflower seed oil), further referred to as the “Urea plus NMF & SBL Complex,” on the expression pattern of diverse skin- and barrier-relevant genes. Furthermore, we hypothesized that the formulation containing this complex shows significantly higher efficacy in terms of moisturization and skin barrier repair than that of the vehicle formulation.

In our studies, we took an integrated approach, investigating effects of the functional moisturizer in female volunteers with dry skin on (i) the ex vivo penetration profile of urea, (ii) the ex vivo expression of genes encoding for proteins involved in skin barrier function, hydration, and lipid metabolism, and (iii) in vivo skin barrier and hydration parameters in subjects suffering from dry to very dry skin.

Materials and Methods

Study Formulations

The ingredients of the functional moisturizer containing the “Urea plus NMF & SBL Complex” (Eucerin 10% Urea Foot Cream, Beiersdorf AG, Hamburg, Germany) and the vehicle are presented in Table 1.

Study 1

The first single-center, randomized, double-blind, vehicle-controlled study was conducted at SIT Skin Investigation and Technology Hamburg GmbH, Hamburg, Germany. In this study, 44 healthy, female subjects (aged 22–65 years) were enrolled. The major inclusion criteria were female gender and a self-reported very dry body skin. Finally, only volunteers with objectively dry to very dry skin were included (corneometer units below 40). Patients with skin diseases or dermatological disorders were excluded from the study. During a 1-week washout preconditioning period, eligible subjects were required to use a special mild skin cleansing product (Doppeldusch Fresh, Beiersdorf AG, Hamburg, Germany) twice daily on their inner forearms for approximately 60 s. During this preconditioning period and throughout the whole study, volunteers had to refrain from using other skin-care products as well as special skin-cleansing products such as bath or shower oils on the arms (inside and outside). Also, intensive UV exposure (solarium or sun) was prohibited.
Table 1. Ingredients of the functional moisturizer containing the “Urea plus NMF & SBL Complex” and its vehicle

| INCI | Moisturizer | Vehicle |
|------|-------------|---------|
| Lactic acid + aqua | X |  |
| Urea | X |  |
| Cholesterol + tocopherol | X |  |
| Carnitine | X |  |
| Aqua + sodium lactate | X |  |
| Ceramide NP | X |  |
| Arginine HCL | X |  |
| Alanine | X |  |
| Glycine | X |  |
| Aqua + sodium PCA | X |  |
| Helianthus annuus seed oil | X |  |
| Sodium chloride | X |  |
| Glycerin | X | X |
| Dimethicone | X | X |
| Octyldodecanol | X | X |
| Hydrogenated coco-glycerides | X | X |
| Ethylhexyl cocoate | X | X |
| Caprylic/capric triglyceride | X | X |
| Sorbitan stearate + aqua | X | X |
| Glyceryl stearate SE | X | X |
| Glyceryl stearate | X | X |
| Sodium cetearyl sulfate | X | X |
| Distarch phosphate | X | X |
| Phenoxethanol | X | X |
| Cetearyl alcohol | X | X |
| Carbomer | X | X |
| Aqua | X | X |

NMF, natural moisturizing factor; SBL, skin barrier lipid; PCA, pyrrolidone carboxylic acid.

On the first study day, test areas were established on the inner forearms for treatment with the verum or the vehicle and baseline measurements were performed. There were 4 test sites, namely 2 on each inner forearm. Three of the sites were treated with the test products, and one site was left untreated and served as a control. Positioning of treatment locations within the test sites was permuted from subject to subject by means of a randomization scheme.

To assess skin hydration, a Corneometer® CM 825 (MDD 4 device, Courage+Khazaka, Cologne, Germany) was utilized according to the EEMCO guidelines [13]. The device had been validated in a multicentric ring study [14].

Ten measurements were taken per test site, and the median result was reported as arbitrary units. For transepidermal water loss (TEWL) measurements, the DermaLab® device (Cortex, Hadsund, Denmark) was used in accordance with the EEMCO guidance [13]. The probe had been validated in earlier randomized, double-blind, vehicle-controlled trials with similar moisturizers, yielding TEWL data paralleled by clinical grading scores of visible dryness and tactile roughness [15]. Moreover, another double-blind study comparing wound-healing ointments confirmed the association of changes in TEWL with investor gradings of dioxime laser wounds [16].

Then, verum and the vehicle were once applied to their allocated test sites by a technician. Each formulation was dispensed from a disposable syringe in an amount equaling 2 μL/cm². The technician then carefully spread the formula using a finger, protected by a finger cot. On the uncovered test sites, formulations could absorb for at least 5 min. Measurements were performed by trained and experienced personnel after acclimatization for at least 30 min under standard atmospheric conditions (21.5°C ± 1.0°C and 50% ± 5% relative humidity).

Twenty-four hours after the controlled application of the test formulations, skin hydration of the test areas was assessed. Further, subjects were supplied with one unit of each test formulation (lasting for 2 weeks) for self-application at home, written usage instructions, and a diary for recording test material application times. The investigator trained subjects in correct self-application for regular use. After 1 week of test formula use at home, a compliance check for all volunteers including an examination of all diaries for correct product application was performed at the institute. Additionally, subjects had to demonstrate the application of the test formulation under supervision of the investigator.

After 2 weeks of regular use (24 h after the last application), skin hydration, and TEWL were assessed again. Furthermore, test sites were stripped with adhesive tape using D-Squame® (DSQ) Standard Sampling Discs (22 mm diameter; CuDerm Corp., Dallas, TX, USA) as described by Knott et al. [17]. Only slight decreases in urea content with the number of tape strips were reported after topical application of 10% urea solution for 3-6 h [18]. However, as the first 2 strips may be contaminated with the product, these were discarded, and the 3rd DSQ per test site was used for stratified urea analyses. The SC protein content on each DSQ was analyzed using the SquameScan™ 850A device (Heiland electronic GmbH, Wetzlar, Germany) by measuring the absorption (%) indicating the protein content (see online suppl. Table 1; for all onlinesupp. material, see www.karger.com/doi/10.1159/000520009).

After measurements, DSQs were rolled up (sample side inwards), placed in provided tubes on dry ice, and stored at −80°C until further use. Twenty-four hours later (48 h after the last application), a final TEWL assessment was performed.

Urea Analytics

We extracted the DSQs with 1 mL of methanol/water 50/50 (v:v). The extract was then filtered using a 0.2-μm PTFE membrane filter ( Pall Corporation Acrodisc 13 mm minispike with 0.2 μm PTFE).

The analytical quantitative determination of urea was performed by means of high-performance liquid chromatography/tandem mass spectrometry using an Agilent HPLC 1200 series (Agilent Technologies GmbH, Waldbronn, Germany) in combination with a 3200 QTRAP (AB Sciex, Darmstadt, Germany). Parameters for high-performance liquid chromatography were as follows: column: Hamilton HPLC anion exchange PRP-100 125 mm 10 μm (Sigma-Aldrich, Taufkirchen, Germany) and mobile phase (gradient): solvent A: water with ammonia containing 2 mmol/L ammonium carbonate (pH 10) and solvent B: acetonitrile. The flow rate was 400 μL/min, and the injection volume 2 μL. Samples were applied to the column at 60% B (0 min) and eluted with 20% solvent B (5 and 12 min) and then 60% solvent B (13 and 18 min). The retention time of urea was 1.5 min.

Electrospray detection was carried out by means of “multireaction monitoring” of the transition of the precursor-ion to a prod-
NMF and Lipids Modulate Gene Expression in Xerosis

Statistics
Statistical analyses were performed using Microsoft Excel 2010 and the Microsoft Excel 2013 (XP; Microsoft Corp., Redmond, WA, USA), the SAS Software Package for Windows V9.4 (SAS Institute GmbH, Heidelberg, Germany), and STATISTICA 12.0 (StatSoft, Inc., Tulsa, OK, USA). All statistical tests were two-sided at significance level alpha = 0.05.

For study I, the less pronounced effect could be expected for TEWL measurements (c.f. delta = 0.75, SD = 1.73). To achieve a power of at least 80% with a paired t-test, a sample of n = 44 was necessary. For corneometry, a higher effect was expected, thus n = 44 was considered sufficient here.

For study II, based on our experience with gene expression analyses in suction blisters of subjects with dry skin in a similar study design [21], we derived empirically the minimum number of subjects needed. Significance (adjusted p value ≤0.05; experiment-wide error rate is controlled) is tested by applying Wilcoxon’s signed rank test with p value adjustment according to Benjamini and Hochberg; in order to control, the false discovery rate was used.

Tolerability
Results showed that all test formulations were well tolerated. Neither an incompatibility reaction nor discomfort was observed or reported for any subject. All subjects completed the studies.

The Novel Moisturizer Improves Skin Hydration and Barrier Integrity
Skin Hydration
The average pretreatment baseline corneometer mean value of 24.6 + 5.6 a.u. on the test sites (inner forearm) indicated the very dry skin condition of the volunteers which did not significantly change during the treatment period as the corneometer values of the untreated control sites show (after 24 h: 2.70 ± 3.46 a.u., after 1 week: 6.97 ± 5.27 a.u.). As illustrated in Figure 1a, in comparison to the vehicle control (7.10 ± 3.46 a.u.), sites treated with verum (10.27 ± 4.49 a.u.) showed a statistically significant
increase in corneometry values 24 h after a single and controlled application \((p < 0.0001)\). Twenty-four hours after the 2-week treatment period, compared to the vehicle control \((12.48 \pm 5.74 \text{ a.u.})\), corneometry values of verum-treated sites were significantly increased to \(15.67 \pm 9.55 \text{ a.u.} \) \((p = 0.0012)\).

**Skin Barrier Function**

As the pretreatment baseline level for TEWL, a mean value of \(7.19 \pm 2.2 \text{ (g/m}^2\text{h})\) was detected on all test sites of the included volunteers. The skin barrier condition of the untreated control sites did not significantly change during the treatment period as shown by the TEWL values \((24 \text{ h: } -0.94 \pm 1.34 \text{ g/(m}^2\text{h) and after 1 week: } -0.42 \pm 1.43 \text{ g/(m}^2\text{h)})\). In comparison to vehicle-control sites \((-1.64 \pm 1.74 \text{ g/(m}^2\text{h)})\), TEWL values of verum-treated areas demonstrated a significant decrease \((-2.23 \pm 1.96 \text{ g/(m}^2\text{h)}) 24 \text{ h after the 2-week treatment period} \((p = 0.0021)\).

Forty eight hours after 14 days of application, verum-treated areas \((-1.78 \pm 1.98 \text{ g/(m}^2\text{h)})\) demonstrated significantly lower TEWL values than the vehicle-treated sites \((-1.07 \pm 1.87 \text{ g/(m}^2\text{h)})\), \(p = 0.0004\), Fig. 1b).

**Urea Penetrates into the Skin**

Figure 1c depicts the urea content in DSQ 24 h after the 2-week treatment period. The average value of urea content detected in the untreated test sites was \(0.18 \pm 0.46 \mu\text{g/DSQ}\). For the vehicle-treated areas, a urea content of \(0.05 \pm 0.06 \mu\text{g/DSQ}\) was determined, while sites treated with verum displayed a urea content of \(1.14 \pm 1.19 \mu\text{g/DSQ}\). Compared to the vehicle-treated site, the urea content in the verum-treated area was significantly increased \((p < 0.0001)\). After verum treatment, a highly significant negative correlation \((-0.53; p < 0.001)\) was detected between DSQ urea content and TEWL.

**The Novel Moisturizer Containing the “Urea plus NMF & SBL Complex” Stimulates Cellular Processes to Maintain Cellular Functions**

First, as shown in Figure 2, relative gene expression data of suction blister roofs from volunteers having applied the novel moisturizer containing the “Urea plus NMF & SBL Complex” for 2 weeks revealed, compared to the vehicle, significant upregulation \((p < 0.05)\) of the following genes involved in skin differentiation and barrier function: transglutaminase 1 \((TGM1)\), involucrin \((IVL)\), loricrin \((LOR)\), filaggrin \((FLG)\), filaggrin family member 2 \((FLG2)\), keratin-10 \((KRT10)\), kallikrein 5 \((SC trypsin enzyme, KLK5)\), kallikrein 7 \((SC chymotryptic enzyme, KLK7)\), caspase-14 \((CASP14)\), cor-

---

**Fig. 1.** NMF and skin-related lipids enhance skin hydration and barrier function in a vehicle-controlled treatment of xerosis. a Skin moisturization was measured by corneometry 24 h after a single product application as well as 24 h after 2 weeks of regular use \((n = 44)\). b Assessment of TEWL was conducted 24 h and 48 h after 2 weeks of regular use \((n = 44)\). c Urea content in DSQs collected 24 h after 2 weeks of regular use \((n = 44)\). Results are shown in a scatter plot as individual values, and the line indicates the mean. Significant differences are marked with an asterisk \(^*\) for \(p < 0.05\) comparison to vehicle; \(^#\) for \(p < 0.05\) comparison to baseline. NMF, natural moisturizing factor; TEWL, transepidermal water loss; DSQ, D-Squame.
neodesmosin (CDSN), occludin (OCLN), and claudin-1 (CLDN1). Second, expression of genes associated with hydration such as aquaporin (AQP)-3 (AQP3) and aquaporin-9 (AQP9) was significantly increased compared to the vehicle. Third, the gene expression levels of markers for skin lipid metabolism such as elongation of very long-chain fatty acids-4 (ELOVL4), sphingomyelin phosphodiesterase (SMPD1), and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) were, compared to the vehicle, significantly upregulated.

**Discussion**

The prevalence of dry skin in the German adult population was demonstrated to be almost 30% of the population older than 16 years [22]. A much higher proportion of xerosis up to 100% was found in geriatric communities in Germany and Thailand [23, 24]. These numbers emphasize the need for a sufficient disease management [22]. An internationally recognized approach in the treatment of xerosis cutis is the application of moisturizers containing lipophilic and hydrophilic active substances.

Hydrophilic compounds include components of the NMF such as urea, amino acids, and PCA. Lipophilic substances related to SBLs include ceramides, cholesterol, and natural oils rich in linoleic acid [1, 4, 5].

Here, we determined the efficacy and molecular mechanisms of a novel moisturizer containing a biomimetic combination of 10% urea and additional NMF components (lactate, amino acids, and PCA) as well as SBLs (ceramide NP, cholesterol, and linoleic acid-rich sunflower seed oil) referred to as the “Urea plus NMF & SBL Complex” in female subjects suffering from dry to very dry skin. First, we investigated changes in skin hydration after treatment with the new formulation compared to the vehicle. As early as 24 h after a single application of the test formulation, corneometry values were significantly increased compared to vehicle-treated areas. This difference was further expanded 24 h after 2 weeks of treatment, indicating that application of the moisturizer improves skin hydration fast and incrementally. These findings were corroborated by our urea bioavailability data and in accordance with recent tape-stripping studies observing significant higher concentration of urea in the deeper SC layers compared to other small solutes [25].

Compared to vehicle treatment, the application of the novel moisturizer with the “Urea plus NMF & SBL Complex” led to significantly reduced TEWL values 24 h and 48 h after the 2-week treatment period. Moreover, the highly significant negative correlation between urea content in DSQs and TEWL underlines the positive effect of urea on skin barrier function. This outcome is in line with earlier studies. Urea has been shown to reduce TEWL [26–29] and improve skin hydration [28–34] in various dry-skin conditions. With respect to hydrating effects, a combination of urea with NMF and SBL was superior to treatment with vehicle alone or topical formulations only containing urea [1, 34]. As with our study, also vehicle-treated sites demonstrated a significant improvement of skin hydration and skin barrier function. Accordingly, a recent review concluded that emollient vehicles with moisturizing effects are therapeutically advantageous on multiple levels [35].
Beyond its humectant effects on the SC, urea belongs to the group of osmolytes, small water-soluble polar molecules with low vapor pressure involved in water homeostasis in the skin [36]. In case of epidermal osmotic stress resulting from dry environmental conditions or skin diseases, urea can replace water and thereby stabilize cell membranes to prevent dehydration-induced structural reorganizations and phase transitions of lipid bilayer systems [37, 38].

Treatment of the SC with urea at reduced relative humidity results in molecular and macroscopic SC responses comparable to those observed by an increase in relative humidity without urea application [39]. Moreover, recent genomic and transcriptomic analyses disclosed that urea modulates the expression of multiple genes involved in epidermal lipid and antimicrobial peptide synthesis, urea transport proteins, keratinocyte differentiation, and desmolysis. Hence, urea profoundly impacts epidermal structure and function as a regulator of hydration, barrier formation, and desquamation [6, 11, 12].

The first step to elucidate the mode of action of the novel functional moisturizer with the “Urea plus NMF & SBL Complex” in more detail was to investigate the bioavailability of urea. By determining the ex vivo penetration profile of urea in DSQs from volunteers after application of the moisturizer for 2 weeks, we confirmed that urea was effectively released from the formulation to the skin.

Next, we elucidated the effects of the “Urea plus NMF & SBL Complex” on the expression of genes encoding for proteins involved in skin hydration, differentiation, lipid metabolism, and barrier function. Although the observed fold changes were rather small, the analysis revealed significant changes for multiple genes associated with specific cellular functions with respect to the comparison verum versus vehicle. All depicted genes showed a significant expression change \( p < 0.05 \); differently expressed genes with a foldchange >1.5 were highlighted [40].

First, we investigated genes involved in skin differentiation and barrier function: Specifically, FLG, FLG2, IVL, TGM1, and LOR play a crucial role in epidermal differentiation [41]. Filaggrin represents a skin barrier protein with an important function in keratin filament alignment [42]. Also, its degradation products yield NMF [43], and FLG gene mutations have been associated with an increased risk for AD and ichthyosis vulgaris [44, 45]. Furthermore, elevating FLG protein levels by 5–10% may provide clinical benefits in the management of patients with dry skin and atopy [44, 46]. Our results are in line with earlier studies reporting that TGM1, IVL, LOR, and FLG mRNA and protein levels were slightly but significantly increased after 10% urea application compared to the untreated skin [12]. The effects of the “Urea plus NMF & SBL Complex” were observed although both study formulations contained glycerin which also upregulates mRNA level expression of FLG and LOR in keratinocytes [47]. However, Hoppe et al. [48] did not find any major changes in gene activity, including LOR and FLG, in patients suffering from AD and/or ichthyosis vulgaris after a 4-week treatment period, with moisturizers containing 20% glycerin or 5% urea, although significant reductions in dryness scores and TEWL were observed. We further investigated the expression of CASP14, a crucial protease involved in FLG catabolism and NMF generation [49]. Differentiation-related KRT10, as well as the cornified envelope-associated proteins IVL and LOR were found to be suppressed in human AD [50]. Additionally, the expression of KRT10 was reduced in dry skin [51] and AD lesions, potentially related to a disturbed barrier function [52]. Moreover, CLDN1 and OCLN are considered relevant to skin barrier function as they are involved in the formation of proteins essential for tight-junction function [53]. In mice, deletion of CLDN1 led to death within 24 h of birth due to massive TEWL [53].

Application of the “Urea plus NMF & SBL Complex” resulted in an increase in CASP14, KRT10, IVL, LOR, CLDN1, and OCLN gene expression, which was accompanied by the observed improvement of skin barrier function, exceeding the expression differences of IVL and LOR reported by Grether-Beck et al. [12] after a 10% urea treatment ex vivo.

Moreover, we observed an induction of gene expression of KLK5, KLK7, and CDSN. Both KLK5 and KLK7 have been demonstrated to cleave CDSN which is crucial in corneocyte cohesion; hence, its degradation is necessary for desquamation [54]. In dry-skin conditions such as winter or atopic xerosis, skin levels of KLK5 and KLK7 are diminished, providing a basis for “corneotherapy” of disturbed desquamation [55]. However, an elevation of KLK5 and KLK7 levels was observed in AD in association with biomarkers also in nonlesional skin, requiring further investigations of epidermal serine protease activity [55, 56].

The second functional cluster we investigated represents genes that are associated with epidermal hydration: AQP3 and AQP9 are members of the aquaglyceroporin family, membrane proteins that build water channels across the cell membrane enabling transport of water and small solutes such as glycerin and urea [57]. Activation of
AQP expression is a prerequisite of sustained epidermal water supply and skin hydration as evidenced by earlier studies demonstrating that mice lacking AQP3 exhibited a reduced glycerol content and a diminished water holding capacity in the epidermis [58]. Also, an AQP3-deficient epidermis displays reduced skin elasticity and delayed wound healing [59]. AQP3 has been linked to keratinocyte proliferation, migration, differentiation, and survival [60]. Here, we show the upregulation of AQP gene expression ex vivo, which was previously only demonstrated in keratinocytes in vitro [12]. These findings indicate efficacy of the “Urea plus NMF & SBL Complex” in AQP3 and AQP9 upregulation after topical application, improving skin hydration inside-out.

The third group of genes that we focused on were genes involved in lipid production and metabolism: the ELO family of proteins is involved in the elongation of long-chain fatty acids. ELOVL4 mRNA increases during keratinocyte differentiation in vivo and in vitro [61]. ELOVL4 plays a crucial role in the synthesis of ω-O-acylceramides, and depletion of these omega-O-acylceramides has been associated with skin conditions exhibiting a skin barrier dysfunction such as AD [62, 63]. Also, studies with mice lacking functional ELOVL4 demonstrate a strong reduction in very-long-chain FFAs and a defective skin water permeability barrier function [63]. SMPD1 encodes for acid sphingomyelinase, converting sphingomyelin to ceramide. In AD, a decreased SMPD1 activity was demonstrated in lesional and nonlesional skin, correlating with reduced SC ceramide content and disturbed barrier function [52]. Cholesterol synthesis is regulated by the enzyme HMG CoA reductase. Following acute barrier disruption, epidermal cholesterol synthesis increases accompanied by an increase in HMGCR activity, protein, and mRNA levels [64]. These earlier findings emphasize the high relevance of the genes we analyzed. Our study revealed a slight but significant upregulation of the mRNA expression of ELOVL4, SMPD1, and HMGCR compared to vehicle-treated sites.

A limitation of the study was the inclusion of female volunteers only. Gender-specific differences in skin response to the investigated complex remain to be clarified in future studies.

Taken together as the outcome, the “Urea plus NMF & SBL Complex” modifies mRNA expression of important epidermal genes beyond its outside-in humectant properties. The gene expression data provide evidence for the induction of cellular epidermal processes resulting in an improved skin hydration and barrier function inside-out, exceeding a passive humectant effect. As hypothesized, the whole complex revealed significant changes in the gene expression pattern of barrier relevant proteins. The expression differences were detected ex vivo in more genes than already described for a 10% urea treatment [12]. These results further elucidate the molecular mechanisms stimulated by the moisturizer. Furthermore, our findings advance our understanding why urea has been the ingredient of choice for the treatment of xerosis for many decades. Future studies will have to investigate its potential role in more specific skin conditions such as atopic, diabetic, and senile xerosis.

Acknowledgments

The authors would like to thank Dr. Silke Gallinat for her support in preparing the manuscript, Ursula Holtzmann for supporting the RNA extraction, and Claudia Rauscher and Andre Rehage for the statistical analyses.

Statement of Ethics

The protocol of study I was approved by an Institutional Review Board of SIT Skin Investigation and Technology Hamburg GmbH, Hamburg, Germany, and the second study was approved by the Independent Ethics Committee Freiburg (feki code 08/2610). For both studies, the recommendations of the current version of the Declaration of Helsinki and the guideline of the International Conference on Harmonization Good Clinical Practice (ICH GCP) were observed as applicable to a nondrug study. All volunteers provided written, informed consent.

Conflict of Interest Statement

Silke Altgilbers, Frank Rippke, Alexander Filbry, Stefanie Conzelmann, Jens-Peter Vietzke, Thorsten Burkhart, Dennis Roggenkamp, and Elke Grönniger are employees of Beiersdorf AG. Dörte Segger is an employee of SGS Institut Fresenius GmbH (former SIT Skin Investigation and Technology), Hamburg, Germany. None of the authors state a conflict of interest.

Funding Sources

The study was sponsored by Beiersdorf AG, Hamburg, Germany.

Author Contributions

S.A., F.R., A.F., S.C., J.-P.V., T.B., D.S., D.R., E.G. D.R. and E.G. conceived and designed experiments. S.A., D.S. T.B., and J.D. performed the experiments. S.A., D.S., T.B., J.-P.V., D.R.,
References

1. Augustin M, Wilsmann-Theis D, Körber A, Kerscher M, Ischtger G, Dippel M, et al. Diagnosis and treatment of xerosis cutis - a position paper. J Dtsch Dermatol Ges. 2019;17(Suppl 7):3–33.

2. Garibyan L, Chieu AS, Elmariah SB. Advanced aging skin and itch: addressing an unmet need. Dermatol Ther. 2013;26(2):92–103.

3. Ständer S, Augustin M, Reich A, Blome C, Ebata T, Phan NQ, et al. International Forum for the Study of Itch Special Interest Group scoring itch in clinical trials. Pruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFS) Special Interest Group scoring itch in clinical trials. Acta Derm Venereol. 2013;93:509–14.

4. Del Rosso JQ, Levin J. The clinical relevance of maintaining the functional integrity of the stratum corneum in both healthy and disease-affected skin. J Clin Aesthet Dermatol. 2011;4(9):22–42.

5. Fowler J. Understanding the role of natural moisturizing factor in skin hydration. Pract Dermatol. 2012;7:36–40.

6. Friedman AJ, von Grote EC, Meckfessel MH. Urea: a clinically oriented overview from bench to bedside. J Drugs Dermatol. 2016;15(5):633–39.

7. Celleno L. Topical urea in skincare: a review. Dermatol Ther. 2018;31(6):e12690.

8. Berardesca E, Cameli N. Non-invasive assessment of urea efﬁcacy: a review. Int J Clin Pract. 2020;74(S187):e13603.

9. Alan Andersen F. Final report of the safety of urea. Int J Toxicol. 2004;24(Suppl 3):1–56.

10. Pan M, Heinecke G, Bernardo S, Tsui C, Levitt J. Urea: a comprehensive review of the clinical literature. Dermatol Online J. 2013;19(11):20392.

11. Schöllmair A, Banke-Bochita J, Bohnsack K, Rippe K, Herrmann WM. Efficacy and safety of Eucerin® 10% urea lotion in the treatment of symptoms of aged skin. J Dermal Ther. 1998;9:175–9.

12. Bovier M, Heinecke G, Bernardo S, Tsui C, Levitt J. Urea: a comprehensive review of the clinical literature. Dermatol Online J. 2013;19(11):20392.

13. Berardesca E, Lodén M, Serup J, Masson P, Rodrigues LM. The revised EEMCO guidance for the in vivo measurement of water in the skin. Skin Res Technol. 2018;24:351–8.

14. Heinrich U, Koop U, Leneuve-Duchemin MC, Osterrieder K, Bießfeldt S, Chkarnat C, et al. Multicentre comparison of skin hydration in terms of physical-, physiological- and product-dependent parameters by the capacitive method (corneometer CM 825). Int J Cosmet Sci. 2003;25(1-2):45–53.

15. Weber TM, Kausch M, Rippe K, Schoellermann AM, Filby AW. Treatment of xerosis with a topical formulation containing glyceryl glucoside, natural moisturizing factors, and ceramide. J Clin Aesthet Dermatol. 2012;5(6):29–39.

16. Trookman NS, Rizer RL, Weber T. Treatment of minor wounds from dermatologic procedures: a comparison of three topical wound care ointments using a laser wound model. J Am Acad Dermatol. 2011;64(3 Suppl):S8–15.

17. Knott A, Achterberg V, Smuda C, Mielke H, Sperling G, Dunckelmann K, et al. Topical treatment with coenzyme Q10-containing formulas improves skin’s Q10 level and provides antioxidative effects. Biofactors. 2015;41(6):383–90.

18. Lodén M, Boström P, Knecke M. Distribution and keratolytic effect of salicylic acid and urea in human skin. Skin Pharmacol Physiol. 1995;8(4):173–8.

19. Kistala U. Suction blister device for separation of viable epidermis from dermis. J Invest Dermatol. 1968;50:129–37.

20. Süel KM, Venzke K, Knufmann-Hartig E, Moll I, Stab F, Wenck H, et al. Tight control of matrix metalloproteinase-1 activity in human skin. Photochem Photobiol. 2003;78:355–60.

21. Schrader A, Siekken W, Kueper T, Breitenbach U, Gattermann C, Sperling G, et al. Effects of glyceryl glucoside on AQP3 expression, barrier function and hydration of human skin. Skin Pharmacol Physiol. 2012;25(4):192–9.

22. Augustin M, Kirsten N, Körber A, Wilsmann-Theis D, Ischtger G, Saubach-Renz P, et al. Prevalence, predictors and comorbidity of dry skin in the general population. J Eur Acad Dermatol Venereol. 2019;33(1):147–50.

23. Hahnel E, Bießfeldt S, Borelli C, Bielfeldt S, Borelli S, Schaller M, et al. Effects of glyceryl glucoside, natural moisturizing factors, and ceramide. J Clin Aesthet Dermatol. 2012;5(8):29–39.

24. Rijvutthikun I, Niyavanavardhana S. Descriptive cross-sectional survey of xerosis in general middle-aged and elderly at Benchakitti Park hospital. RSU International Research Conference; 2020. p. 369–79.

25. Intarakumhaeng R, Alsheddi L, Wasanathop A, Shi Z, Li SK. Skin permeation of urea under finite dose condition. J Pharm Sci. 2019;108:987–95.

26. Lodén M. Urea-containing moisturizers influence barrier properties of normal skin. Arch Dermatol Res. 1996;288(2):103–7.

27. Lodén M. Barrier recovery and influence of irritant stimuli in skin treated with a moisturizing cream. Contact Dermatitis. 1997;36(5):256–60.

28. Borelli C, Bießfeldt S, Borelli S, Schaller M, Korting HC. Cream or foam in pedal skin care: towards the ideal vehicle for urea used against dry skin. Int J Cosmet Sci. 2001;33(1):37–43.

29. Pan M, Heinecke G, Bernardo S, Tsui C, Levitt J. Urea: a comprehensive review of the clinical literature. Dermatol Online J. 2013;19(11):20392.

30. Schöllmair A, Banke-Bochita J, Bohnsack K, Rippe K, Herrmann WM. Efficacy and verträglichkeit von Eucerin® 10% urea lotion in the treatment of symptoms of aged skin. J Dermal Ther. 1998;9:175–9.

31. Schöllmair A, Bohnsack K, Stephan K, Banke-Bochita J, Herrmann WM, Rippe K. Wirksamkeit und verträglichkeit von Eucerin salbe 10% urea bei atopischem Altershaut-Ergebnisse einer Vehikel-kontrollierten klinischen Doppelblindstudie. Z Hautkr. 1999;10(74):557–62.

32. Bohnsack K, Tausch I, Gassmüller J, Rippe F. Wirksamkeit auf das Symptom trockene Haut und Langzeitverträglichkeit von Laceran® Lotion 10% urea bei Patienten mit atopischem Ekzem. Z Hautkr. 1997;1(72):34–9.

33. Wilhelm KP, Schöllmair A, Bohnsack K, Wilhelm D, Rippe F. Wirksamkeit und Verträglichkeit einer topischen Zubereitung mit 10% Urea (Laceran Salbe 10% Urea) bei Neurodermitis. Akt Dermatol. 1998;24:26–30.

34. Weber TM, Kausch M, Rippe K, Schoellermann AM, Filby AW. Treatment of xerosis with a topical formulation containing glyceryl glucoside, natural moisturizing factors, and ceramide. J Clin Aesthet Dermatol. 2012;5(8):29–39.

35. Danby SG, Draelos ZD, Stein Gold LF, Cha A, Vlahos B, Aikman L, et al. Vehicles for atopic dermatitis therapies: more than just a placebo. J Dermalog Treat. 2020;1–14. [published online ahead of print, 2020 Jul 16].

36. El-Chami G, Haslam IS, Steward MC, O’Neill CA. Role of organic osomolytes in water homeostasis in skin. Exp Dermatol. 2014;23(8):534–7.
NMF and Lipids Modulate Gene Expression in Xerosis

37 Costa-Balogh FO, Wenersström H, Wadsö L, Sparr E. How small polar molecules protect membrane systems against osmotic stress: the urea-water-phospholipid system. J Phys Chem B. 2006;110(47):23845–52.

38 Pham QD, Wolde-Kidan A, Gupta A, Schlaich A, Schneek E, Netz RR, et al. Effects of urea and TMAO on lipid self-assembly under osmotic stress conditions. J Phys Chem B. 2018;122(25):6471–82.

39 Mojumdar EH, Pham QD, Topgaard D, Sparr E. Skin hydration: interplay between molecular dynamics, structure and water uptake in the stratum corneum. Sci Rep. 2017;7(1):15712.

40 McCarthy DJ, Smyth GK. Testing significance relative to a fold-change threshold is a TREAT. Bioinformatics. 2009;25(6):765–71.

41 Chen CS, Lakker RM, Rodeck U, Risse B, Jensen PJ. Use of a serum-free epidermal culture model to show deleterious effects of epidermal growth factor on morphogenesis and differentiation. J Invest Dermatol. 1995;104(1):107–12.

42 Brown SJ, Irvine AD. Atopic eczema and the filaggrin story. Semin Cutan Med Surg. 2008;27(2):128–37.

43 Mao-Qiang M, Fowler AJ, Schmuth M, Lau P, Brown SJ, Irvine AD. Atopic eczema and the role of filaggrin in the stratum corneum. J Invest Dermatol. 2012;132(1):10–11.

44 Kim SY, Bernard D, Schmidt R, et al. Multifaceted analyses of epidermal serine protease activity in patients with atopic dermatitis. Int J Mol Sci. 2020;21:913.

45 Rawlings AV, Voegeli R. Stratum corneum proteases and dry skin conditions. Cell Tissue Res. 2013;351(2):217–35.

46 Feingold KR. Thematic review series: skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis. J Lipid Res. 2007;48(12):2351–46.